期刊文献+

EGFR靶向药物西妥昔单抗在结直肠癌治疗中的应用进展 被引量:8

Prospect of cetuximab in the treatment of colorectal cancer
原文传递
导出
摘要 结直肠癌是最常见的恶性肿瘤,随着人类平均寿命的提高,生存环境及生活方式的改变,近年来结直肠癌的发病率呈逐年上升趋势,在发达国家及我国经济发达地区,结直肠癌的发病率已上升至恶性肿瘤的第2位。全球每年新增病例约100万,死亡病例约50万,结直肠癌已经成为全球恶性肿瘤导致死亡的主要原因之一。近年来分子靶向药物的出现使晚期结直肠癌患者的治疗得到了明显的改善,本文就结直肠癌靶向治疗的现状及研究进展做一综述。 Colorectal cancer is one of the most common malignant tumors. With the improvement of living condition and peoples' life-span, the incidence rate of colorectal cancer has been ascending year by year. In developed countries and devel- oped district of China, colorectal cancer has become the second common malignant tumor. More than one million people were diagnosed as with colorectal cancer, and 500,000 of them died yearly. Colorectal cancer is one of the most common reasons of the death of cancer patients. With the development of molecular targeted agents research, the therapeutic effects for colorectal cancer patients have been improved, and the current status and prospect of targeted therapy for colorectal cancer patients were introduced in this review.
出处 《中华消化外科杂志》 CAS CSCD 北大核心 2013年第7期556-560,共5页 Chinese Journal of Digestive Surgery
基金 国家基础研究项目(2009eB521705) 国家自然科学基金(30672399、30973410、30971337)
关键词 结直肠肿瘤 靶向治疗 Colorectal neoplasms Targeted therapy
  • 相关文献

参考文献4

二级参考文献44

  • 1沈云婕,朱珺.新型分子靶向抗癌药物的研究进展[J].世界临床药物,2007,28(5):288-292. 被引量:5
  • 2梁佩芳,顾勇,杨道茂,欧阳明安.从天然产物中寻找蛋白激酶C抑制剂的研究进展[J].中国药物化学杂志,2007,17(4):254-262. 被引量:4
  • 3焦宇,陆涛.抗肿瘤药物Raf激酶抑制剂的研究进展[J].海峡药学,2007,19(8):1-5. 被引量:7
  • 4Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J].Science,2004,304:1497-1500.
  • 5Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350:2129-2139.
  • 6Mu XL,Li LY,Zhang XT,et al.Evaluation of safety and efficacy of gefitinib (‘iressa',ZD1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer:experience form a compassionate-use programme[J].BMC Cancer,2004,4:51-59.
  • 7Mu XL,Li LY,Zhang XT,et al.Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer[J].Clin Cancer Ras,2005,11(12):4289-4294.
  • 8Bell DW,Lynch TJ,Haserlat SM,et al.Epidermal growth factor receptor mutation and gene amplification in non-smallcell lung cancer:molecular analysis of the IDEAL/INTACT gefitinib trials[J].J Clin Oncol,2005,23(31):8081-8092.
  • 9Parra HS,Cavina R,Latteri F,et al.Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘ Iressa',ZD1839)in non-small-cell lung cancer[J].Br J Cancer,2004,91:208-212.
  • 10Pao W,Miller V,Zakowski M,et al.EGF receptor gene mutations are common in lung cancers from "never smokers"and are associated with sensitivity of tumors to gefitinib and erlotinib[J].Proc Natl Acad Sci USA,2004,101:13306-13311.

共引文献20

同被引文献99

引证文献8

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部